first look phew
take like read morn abbott result came better expect top bottom line organ
sale growth abbott guidanc littl believ market acknowledg abbott guidanc
bit ideal want see bit upsid driver surprisingli stronger perform
intern nutrit diabet also continu major growth driver sale driven libr
help off-set under-perform busi devic neuromod/crm result total devic sale also
expect ep beat view high qualiti beat net/net think stock trade higher
compani host confer call et web link listen commentari outlook focu
sustain sale growth perform within intern nutrit diagnost major growth driver libr alin
pipelin updat section detail look
feel free reach question kristen
snapshot sale ep beat
sale ere million refinitiv consensu million estim million
organ sale grow th hich abbott guidanc littl believ market acknow ledg
abbott guidanc bit ideal ant see bit perform led medic devic
sale ere nutrit stronger expect quarter come grow th versu guidanc low mid-singl
digit driven perform intern busi epd grow th expect diagnost overal
line reflect difficult comp expect due flu ithin rapid diagnost franchis
ep ere estim street high end compani guidanc rang
rel estim upsid driven better sale perform tax rate came bit higher
expect make quarter even solid oper beat
ep abbott maintain ep guidanc repres doubl digit grow th mid-point street
consensu estim current abbott expect ep hich bracket current consensu
estim
sale abbott comment organ sale grow th expect press releas usual comment
earn expect compani reiter prior guidanc organ sale grow th rang
result greater detail
pleas note y/i chang refer organ constant currenc basi unless otherwis specifi
sale ere million constant currenc basi hich line ith guidanc high singl digit grow th
grow th driven usual suspectsdiabet driven libr sale hich total structur heart
electrophysiolog perform heart failur significantli step quarter
 ere anticip driven momentum clinic studi hich help abbott gain share mdt-
overw vascular sale perform expect dow neuromodul eaker dow
 rhythm manag dow
diagnost sale ere million oper abbott guid legaci diagnost molecular point
grow th mid- high-singl digit rapid diagnost rel flat reflect tough flu comp
laboratori sale ere strong reflect strong grow th intern us
molecular diagnost sale ere dow declin ou dow off-set increas us abbott
receiv ce mark approv alin system march outlook like improv
point diagnost sale ere dow global driven larg ou busi dow though us franchis
 also dow y/i
rapid diagnost legaci aler busi sale ere declin global slightli ors abbott
guidanc flattish perform
nutrit sale ere million organ basi hich compani guidanc low -to-mid singl
digit grow th abbott discontinu ea busi ithin adult nutrit franchis exclud exit
nutrit sale grow th driven strong perform constant currenc basi ou sale ere
 hile us ou grow th strong pediatr adult pediatr abbott
comment grow th strong asia latin america
pediatr sale ere global hile adult global driven aforement strong intern
sale ere million constant currenc basi hich line ith compani guidanc mid-singl digit
emerg market sale ere sale region ere dow expect due discontinu
gross margin slightli manag guidanc estim compar prior
year believ margin compress mainli function fx
sg sale in-lin ith abbott guidanc bit smidgen estim
prior year rate ith abbott show ing good leverag execut cost synergi cost manag
 sale hich fairli in-lin ith guidanc estim spend even ith
prior year
oper margin slightli estim ith prior year
interest expens million significantli reduc prior year abbott paid billion debt
tax rate hich perhap bit manag guidanc around estim
ep ere estim street compani guidanc rang
listen today call et
compani ill host confer call et eb link ell listen commentari
guidanc updat abbott expect full year sale grow th rang segment manag expect epd
sale grow th mid- high-singl digit nutrit grow th low mid-singl digit legaci diagnost grow th mid-
high-singl digit rapid diagnost grow th low mid-singl digit medic devic sale grow th high-singl
digit abbott expect ep ill listen updat guidanc
commentari freestyl libr libr abbott continu glucos monitor signific driver behind grow th
last year sale doubl around billion contribut overal grow th call januari
manag note ad patient quarter bring total million peopl ith estim tw o-
third type balanc type diabet abbott receiv ce mark eu approv freestyl libr octob
latest gener system offer option real-tim alarm use bluetooth technolog abbott launch system
roll basi throughout europ understand product current avail germani call januari
manag comment freestyl libr come shortli hich believ market interpret
mid-year/summ ill listen updat time approv
commentari alin alin abbott latest diagnost instrument famili system roll europ
contribut strong grow th lab march abbott receiv ce mark alin diagnost system test
assay hile alin instrument approv us abbott ait critic mass assay
launch launch us expect later year hich view bode ell us sale grow th beyond
 ill listen reaffirm us launch later year
commentari mitraclip mitraclip abbott transcathet mitral valv repair tmvr system estim sale around
million last fall abbott releas favor coapt trial result hich show ed superior medic therapi reduc
hospit death patient ith sever secondari function mitral regurgit mr march fda grant
abbott expand indic includ sever secondari mr previous product indic use degen
mr ill listen updat mitraclip sale track follow ing coapt result expect grow th
year
commentari pipelin product abbott host new product ithin medic devic busi includ sever
 ithin structur heart busi ill listen updat pipelin
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line grow th prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific
exposur emerg market hich given fx rate could pressur ep new product central posit view approv
adopt new product therefor anoth risk risk includ signific reimburs action medic devic product
recal fda arn letter govern regulatori action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
